ReviewJournal of molecular medicine (Berlin, Germany)2025
Molecular insights into irisin's role in the regulation of programmed cell death: mechanisms and therapeutic potential.
Review in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Irisin Potentiates 5-fluorouracil Cytotoxicity in HT-29 Colon Cancer Cells through Enhanced Apoptosis and Transcriptional Modulation of Adenosine Monophosphate-activated Protein Kinase/Mammalian Target of Rapamycin Signaling.International journal of applied & basic medical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Physical activity is widely accepted for its myriad health benefits, serving as protective mechanisms against many chronic diseases. At the molecular level, exercise exerts its beneficial effects partly through the release of myokines, particularly irisin, which is cleaved from its precursor fibronectin type III domain-containing protein 5 and subsequently secreted from skeletal muscles in response to exercise. Irisin plays a pivotal role in metabolic regulation by inducing the browning of white adipose tissue, enhancing energy expenditure, attenuating insulin resistance, and improving systemic metabolism. In addition to its metabolic functions, irisin has received significant attention for its involvement in the regulation of several forms of programmed cell death such as apoptosis, ferroptosis, pyroptosis, and autophagy in recent years. The newfound interest stems from its potential to modulate cell survival and recycling mechanisms, positioning irisin as a promising chemical for treating a wide range of diseases characterized by aberrant cell death processes such as cardiovascular diseases, ischemia/reperfusion injury, and diabetes. This review therefore aims to collate and discuss the latest evidence on irisin's role in programmed cell death regulation and exploring the implications of these effects for disease intervention. Furthermore, the review identifies the existing knowledge gaps, emphasizing the necessity of understanding irisin's molecular mechanisms of action and the development of therapeutic applications to fully leverage its health-promoting potential.
Indexed as
Identifiers
41452463What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.